we report a case of an elderly patient with metastatic castration-resistant prostate cancer, initially treated with abiraterone acetate (1,000 mg/day) combined with LH-RH antagonist, prednisone (10 mg/day), and zoledronic acid to manage bone metastases. In consideration of his poor performance status, radiological and biochemical progression of the disease, we decided to switch abiraterone to enzalutamide (160 mg/day). due to adverse events, we reduced enzalutamide to a dose of 80 mg/day. currently, the disease is under control despite the use of a low dose of enzalutamide.
Rossi, L., Cimino, G., Gozzi, E., Sinjari, M., Brandi, M., Ceddia, S., et al. (2021). Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report. CASE REPORTS IN ONCOLOGY [10.1159/000514979].
Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report
Filippi L;
2021-01-01
Abstract
we report a case of an elderly patient with metastatic castration-resistant prostate cancer, initially treated with abiraterone acetate (1,000 mg/day) combined with LH-RH antagonist, prednisone (10 mg/day), and zoledronic acid to manage bone metastases. In consideration of his poor performance status, radiological and biochemical progression of the disease, we decided to switch abiraterone to enzalutamide (160 mg/day). due to adverse events, we reduced enzalutamide to a dose of 80 mg/day. currently, the disease is under control despite the use of a low dose of enzalutamide.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
